Palantir Stands Strong Amid Tariff Challenges

Published 1 days agoPLTR

Palantir Stands Strong Amid Tariff Challenges

Palantir Technologies Inc. has recently emerged as a potentially attractive investment amid new tariff developments. This resilience can be attributed to its software-centric business model, which enables the company to effectively navigate the supply chain disruptions often seen in industries impacted by tariffs, as reported by Gurufocus.

The company has demonstrated strong financial performance, with a remarkable 36% increase in revenue year over year in Q4 FY24. Looking ahead, projections for FY25 suggest continued growth, according to Monexa.ai. Analysts also point out that Palantir's operations are less vulnerable to international tariffs, making it a relatively secure investment option.

According to Hoven Equity, some analysts believe that Palantir's current stock price may be undervalued, presenting potential for an upswing despite broader market volatility. As of May 31, 2025, the company's stock is trading at $131.78, showcasing investor confidence amidst the ongoing tariff-related market fluctuations.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Eli Lilly Strengthens Obesity Portfolio Amid Rising Market Performance

Eli Lilly Strengthens Obesity Portfolio Amid Rising Market Performance

3 minutes agoLLY

Eli Lilly continues to reinforce its strategic positioning in the obesity and diabetes treatment market, though no partnership with Camurus has been announced. Instead, Lilly has been expanding its portfolio through targeted acquisitions and product approvals, a move that aligns with its broader goal to lead in innovative therapies for weight loss and diabetes. In July 2023, Eli Lilly acquired Versanis, a privately held company known for its obesity drugs, for an impressive $1.93 billion. This acquisition was strategic in bolstering Lilly's pipeline of weight loss treatments. Furthermore, in November 2023, the FDA approved the use of tirzepatide, marketed as Zepbound for weight loss, under its established brand Mounjaro, marking a significant shift in available treatment options for weight-related conditions, reported CNN. From a financial perspective, Eli Lilly's strategy has paid off, with the company reporting a $4.41 billion profit in the fourth quarter of 2024. This success is largely attributed to strong sales of its diabetes and obesity medications, Mounjaro and Zepbound. As of June 3, 2025, Eli Lilly's stock is trading at $752.99, showing a modest increase. These developments highlight Eli Lilly's significant investment in advancing solutions for obesity and diabetes in the competitive pharmaceutical landscape.

Truist Securities Alters Oshkosh Corporation's Price Target

Truist Securities Alters Oshkosh Corporation's Price Target

17 minutes agoOSK

Truist Securities has revised its outlook on Oshkosh Corporation, retaining a 'Hold' rating while making several adjustments to its price target. Initially, the price target was increased from $113 to $116. However, it was subsequently reduced from $116 to $109, and later further decreased to $94. These changes signify Truist Securities' ongoing evaluation of Oshkosh's stock potential amid current market dynamics. This series of adjustments highlights how the firm's perception of the company's prospects and broader market conditions have influenced its analysis, as reported by Webull. Oshkosh Corporation, a prominent player in the industry, frequently finds itself subject to analyst scrutiny. The latest changes in Truist's price target may prompt stakeholders to reconsider their strategies, but the 'Hold' rating suggests a cautious approach toward the stock.

Capital One Accused of Diverting Affiliate Commissions

Capital One Accused of Diverting Affiliate Commissions

32 minutes agoCOF

Capital One is currently embroiled in a legal battle with social media creators who claim that the bank's browser extension, Capital One Shopping, illegally rerouted millions of dollars in commissions. The creators assert that the extension overrode their tracking codes, misleadingly attributing product referrals to Capital One instead of the creators themselves. Reuters reported that this lawsuit, filed in the Eastern District of Virginia, has drawn attention due to its potential implications on affiliate marketing practices. The complaint accuses Capital One of unjust enrichment, interfering with contracts, and breaching the Computer Fraud and Abuse Act. The creators argue that the bank's actions have cost them significant income and violated legal standards. Notably, similar lawsuits have been filed against Microsoft and PayPal for their respective shopping extensions, indicating a broader issue within the industry. Capital One has firmly denied the accusations, stating that its shopping extension neither replaces affiliate marketers' cookies nor misattributes commissions. The bank emphasized that merchants, not its software, determine commission allocations. While the case continues, it raises important questions about the use and impact of shopping extensions on digital marketing and influencer income strategies.

Incyte's Stock Rises on Announcement of Thrombocythemia Therapy Data

Incyte's Stock Rises on Announcement of Thrombocythemia Therapy Data

48 minutes agoINCY

Incyte Corporation's stock is on the rise following the company's announcement of new data presentations related to its thrombocythemia asset. The biotech firm revealed plans to discuss its mCALR-targeting molecule (INCA33989) during an upcoming conference, marking a significant step forward in their research efforts. INCA33989 is being developed as a first-in-class targeted therapy for patients with myelofibrosis (MF) and essential thrombocythemia (ET) who carry the mCALR gene mutation. With between 25% to 35% of patients with MF and ET affected by this mutation, the therapy could address a substantial patient population. Reuters noted that Incyte is already enrolling participants for Phase I studies, with key data releases anticipated by 2025. Incyte's announcement comes amidst what appears to be a promising development pipeline. Investors are particularly interested in how this therapy could potentially enhance the company's footprint in the field of targeted treatments for serious blood disorders. As the market watches closely, the stock’s positive response is indicative of the optimism surrounding these future prospects.